We are redirecting you to the source. If you are not redirected in 3 seconds, please click here.

Chief Science Officer at BIO. Remote Location: Remote. Bio Protocol is building the next generation of . scientific AI agents. - systems that help scientists reason, plan, and experiment with rigor and transparency. Our mission is to accelerate discovery by creating agents that are reliable, explainable, and grounded in evidence. We’re a team of engineers and scientists working at the intersection of AI systems, knowledge infrastructure, and experimental biology.. Why this role exists. BIO is entering a phase where scientific ambition must deliver repeatable, credible outcomes at portfolio scale. We need senior leadership to evaluate, prioritize, and support multiple assets while improving the systems that guide scientific decisions.. The Chief Science Officer (CSO) will set scientific direction across BIO’s portfolio, raise the bar on quality, and turn ideas into assets that can be supported, commercialized, and adopted. This is not a purely academic or single-project role; the right person operates across science, portfolio strategy, execution, talent, and real-world constraints, helping BIO become increasingly AI-native.. A key requirement is exposure to the drug development and approval process, having observed programs through preclinical, IND-enabling, clinical, and regulatory stages, even if not directly leading them. This ensures scientific decisions translate into real-world outcomes.. What the CSO will actually do. 1. Own BIO’s portfolio-level scientific direction. Review projects launching on BIO Protocol, maintain a clear portfolio view of what's strongest and most promising, and make judgment calls on what to prioritize and what not to pursue.. 2. Lead scientific diligence and decision support. Build and run scalable diligence processes to assess scientific credibility, risk, and upside - translating reviews into clear decision support for prioritization and go/no-go calls across the portfolio.. 3. Be a scientific counterpart to founders, researchers, and partners. Act as a trusted sparring partner to founders, research teams, and DAO leaders - helping refine hypotheses, stress-test approaches, and surface risks early. Externally, represent BIO credibly with academics, biotech operators, investors, and ecosystem partners.. 4. Translate science into strategy, execution, and commercialization. Work closely with Bio teams to turn scientific work into structured programs, milestones, and commercialization paths. Contribute to positioning, narrative, partnerships, and adoption strategy for portfolio assets.. 5. Help allocate resources across the portfolio. Support decisions around how BIO resources (e.g., marketing, growth support, market-making) are allocated across assets - directing attention toward projects that are performing well and demonstrating real scientific and market traction.. 6. Build an AI-native scientific operating model. Become deeply AI-enabled in how scientific work is conducted. Work closely with BIO’s systems and knowledge infrastructure to build AI-driven workflows for research review, synthesis, evaluation, and internal knowledge management - so scientific judgment scales with the platform.. 7. Scientist and researcher acquisition & advisory. Develop and execute a strategy to recruit top-tier researchers and scientists from leading institutions - leveraging academic networks, partnerships, and conferences - and oversee their end-to-end onboarding into the BIO ecosystem.. 8. Strategic advisory for researchers and DAOs. Provide white-glove advisory to researchers and DAO leaders on governance, tokenomics, operations, funding, and long-term sustainability to help them launch and scale effectively.. 9. DAO education and enablement. Ensure researchers and DAO teams can navigate BIO's services through workshops, training sessions, and hands-on consultations.. 10. DAO business model development and improvement. Work with DAO founders to refine and optimize business models, conducting regular evaluations to identify opportunities for improvement and scalability.. 11. Science communication and positioning. Advise DAOs on scientific communication to ensure they remain credible, compelling, and attractive to researchers, contributors, partners, and investors.. 12. Cross-departmental collaboration. Collaborate cross-functionally with product, legal, compliance, marketing, and Molecule Core teams to ensure DAOs are launched in alignment with strategic objectives and regulatory requirements.. 13. Thought leadership and external representation. Stay current on scientific and biotech trends, and represent BIO at conferences and industry events to raise visibility, attract talent, and build partnerships.. 14. Lead the Science team and support the DAO program. Lead and grow BIO's Science team - hiring, mentoring, and managing performance to ensure the team excels.. The profile we’re looking for. A strong scientific foundation (PhD or equivalent depth) combined with experience outside of pure academia. This person should have meaningful exposure to the drug development and approval process, having witnessed one or more programs progress through preclinical development, IND-enabling studies, clinical trials, and regulatory interaction even if they were not directly executing the program.. Experience that really matters. Senior scientific leadership with portfolio exposure (e.g., biotech fund, public biotech vehicle, hedge fund, or similar portfolio-research environment). Demonstrated understanding of drug development realities, regulatory risk, and translational challenges. Experience advising, mentoring, or leading researchers and scientific teams. Comfort balancing scientific depth with execution, systems, prioritization, and commercialization. Interest in (and openness to) becoming AI-native in how scientific work is done. Metrics & KPIs. Number of researcher-led DAOs launched with top-tier academic credentials. Researcher NPS and retention rates across the ecosystem. Quality and progress of scientific assets under management. Funds allocated toward science and efficiency of deployment. IP generation, commercial viability of IP, and long-term DAO sustainability. How this differs from the previous phase. In earlier phases, BIO emphasized exploration, momentum, and narrative. At this stage, we need more executional gravity and follow-through: clearer prioritization, stronger talent density, better decision systems, and confidence in knowing when to double down - and when to say no.. What success looks like after 12 months. Clarified BIO’s scientific and talent strategy at the portfolio level. Improved the quality and credibility of launched projects and DAOs. Built scalable diligence, talent acquisition, and advisory systems informed by drug development exposure. Developed a strong working partnership with Bio Teams, and Molecule Core. Helped BIO ship fewer things better while increasing trust with researchers, partners, and token holders. Overall, this is not a figurehead role. We are looking for a hands-on, portfolio-minded scientific leader who understands how science becomes medicine, has observed drug development and approval processes firsthand, and can help BIO mature as a scientific organization without losing what makes it distinctive.